Compare AFYA & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AFYA | MRVI |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2019 | 2020 |
| Metric | AFYA | MRVI |
|---|---|---|
| Price | $14.82 | $7.08 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $17.65 | $7.83 |
| AVG Volume (30 Days) | 460.2K | ★ 2.3M |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.58% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | $7.66 | $14.01 |
| Revenue Next Year | $7.06 | $6.20 |
| P/E Ratio | $9.30 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.62 | $2.55 |
| 52 Week High | $16.16 | $9.42 |
| Indicator | AFYA | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 65.97 | 45.42 |
| Support Level | $13.43 | $5.54 |
| Resistance Level | $14.84 | $7.60 |
| Average True Range (ATR) | 0.50 | 0.42 |
| MACD | 0.27 | -0.06 |
| Stochastic Oscillator | 99.38 | 7.82 |
Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergraduate, deriving key revenue provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.